Needham Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.4%

Neg 0% Neu 90.4% Pos 0%

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $185 price target.

Comments

No comments yet. Be the first!